Compare
Sonoma Pharmaceuticals, Inc. vs Nephros Inc vs Vivos Therapeutics, Inc. vs DarioHealth Corp.
| Latest fiscal year | Sonoma Pharmaceuticals, Inc. SNOA | Nephros Inc NEPH | Vivos Therapeutics, Inc. VVOS | DarioHealth Corp. DRIO |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $19.53M | $18.79M | $17.44M | $22.36M |
| Revenue growth (YoY) | +36.7% | +32.7% | +16.0% | -17.3% |
| Gross margin | 38.0% | 61.9% | 60.4% | 56.6% |
| Operating margin | -12.6% | 6.1% | -114.1% | -163.9% |
| Net margin | -16.3% | 6.4% | -121.4% | -186.6% |
| Net income | -$3.17M | $1.19M | -$21.17M | -$41.71M |
| EPS (Diluted) | -$1.89 | $0.11 | -$2.07 | $10.12 |
| Operating cash flow | -$3.93M | $1.60M | -$15.26M | -$25.94M |
| Free cash flow | -$4.12M | n/a | -$17.60M | -$26.08M |
| Cash & equivalents | $2.40M | $5.40M | $2.03M | $21.80M |
| Total assets | $13.96M | $13.64M | $25.15M | $110.08M |
| Total liabilities | $10.87M | $3.44M | $26.70M | n/a |
| Shareholders' equity | $3.10M | $10.20M | -$1.49M | $67.92M |
| Return on year-end equity | -102.6% | 11.7% | n/a | -61.4% |
| Shares outstanding | 1.80M | 10.64M | 9.29M | 6.91M |
Revenue, most recent five fiscal years
| Fiscal year | Sonoma Pharmaceuticals, Inc. | Nephros Inc | Vivos Therapeutics, Inc. | DarioHealth Corp. |
|---|---|---|---|---|
| Latest | $19.53M Ended 2026-03-31 | $18.79M Ended 2025-12-31 | $17.44M Ended 2025-12-31 | $22.36M Ended 2025-12-31 |
| 1 year earlier | $14.29M Ended 2025-03-31 | $14.16M Ended 2024-12-31 | $15.03M Ended 2024-12-31 | $27.04M Ended 2024-12-31 |
| 2 years earlier | $12.73M Ended 2024-03-31 | $14.24M Ended 2023-12-31 | $13.80M Ended 2023-12-31 | $20.35M Ended 2023-12-31 |
| 3 years earlier | $13.27M Ended 2023-03-31 | $9.97M Ended 2022-12-31 | $16.02M Ended 2022-12-31 | $27.66M Ended 2022-12-31 |
| 4 years earlier | $12.63M Ended 2022-03-31 | $10.22M Ended 2021-12-31 | $16.89M Ended 2021-12-31 | $20.51M Ended 2021-12-31 |